arrow
W

William J. Aronson

veterans health administration (vha)
H指数:70
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

COMPARISON OF EMBARK AND EAU CRITERIA TO IDENTIFY HIGH-RISK PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY

比较EMBARK和EAU标准以识别根治性前列腺切除术后生化复发的高风险患者

2026-05-010
PRE
A WEIGHTED SCALE TO IDENTIFY EMBARK-LIKE PATIENTS AT HIGH-RISK FOR PROGRESSION AND MORTALITY AFTER BIOCHEMICAL RECURRENCE (BCR) WHO MAY BENEFIT FROM EARLY INTENSIFIED ADT

一种加权评分系统,用于识别在生化复发(BCR)后可能受益于早期强化雄激素剥夺疗法(ADT)的高风险进展和死亡率的EMBARK样患者

2026-05-010
PRE
Consensus Recommendations for Disease-and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel

关于晚期前列腺癌患者疾病和治疗相关疲劳的共识建议:一项改良德尔菲专家组研究

2026-05-010
PRE
ARE WE OPERATING ON THE SAME PATIENTS OVER THE PAST 2 DECADES? 20-YEAR TRENDS IN RADICAL PROSTATECTOMY DEMOGRAPHICS, CLINICOPATHOLOGY, AND OUTCOMES FROM A TERTIARY ACADEMIC CENTER AND MULTI-INSTITUTIONAL COLLABORATIVE

过去20年我们是否在为同一类患者进行手术?来自三级学术中心和多家机构合作的数据显示,根治性前列腺切除术的人口统计学特征、临床病理学和结局的20年趋势

2026-05-010
PRE
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer

表征全人群基因组风险分布,以开发用于临床局部前列腺癌患者预后判断的新型临床-基因组风险系统

2025-12-090
OA
Pooled Analysis of the SOLAR and SATURN Clinical Trials Comparing Progression of Synchronous Versus Metachronous Prostate-specific Membrane Antigen–defined Oligometastatic Prostate Cancer Following Systemic and Tumor-directed Therapy

SOLAR和SATURN临床试验的合并分析:比较系统性治疗和肿瘤定向治疗后,同步与异时性前列腺特异性膜抗原定义的寡转移性前列腺癌的进展情况

2025-06-010
PRE
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer

预测中、低风险前列腺癌男性转移风险极高的不良病理的替代定义

CANCER
IF5.1
2025-01-020
PRE
Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study
2024-08-120
PRE
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer
2024-08-010
PRE
Addressing racial disparities in prostate cancer pathology prediction models: external validation and comparison of four models of pathological outcome prediction before radical prostatectomy in the multiethnic SEARCH cohort
2024-04-110
PRE